Target intelligence / Profile preview

Long intergenic non-protein coding RNA 1170 (LINC01170)

Target
LINC01170
Molecular classification
Long non-coding RNA (lncRNA), Intergenic non-coding RNA (lincRNA)
01

Overview

LINC01170 (Long intergenic non-protein coding RNA 1170) is an intergenic long non-coding RNA located on chromosome 5q23.2. It is classified as a lincRNA, defined by its length (>200 nt) and its lack of overlap with protein-coding genes. LINC01170 is overexpressed in endometrial carcinoma and functions as an oncogene by promoting cell proliferation, cell cycle progression, and inhibiting apoptosis via the PI3K/AKT signaling pathway. Knockdown experiments indicate that reduction of LINC01170 leads to decreased proliferation, increased cell cycle arrest, and apoptosis in endometrial cancer cells. Its expression level correlates with disease stage and prognosis, making it a putative therapeutic and diagnostic target in oncology.

Other names
LOC107986448LINC01170long intergenic non-protein coding RNA 1170
02

Mechanism of action

When upregulated: *Promotes cancer progression* by activating AKT signaling, leading to increased cell survival and proliferation. When inhibited or knocked down: Decreases AKT activity, arrests cell cycle, increases apoptosis in endometrial cancer cells.

03

Biological functions

Regulation of cell proliferationModulation of cell cycle progression (especially G0/G1 arrest)Inhibition/induction of apoptosisUpregulation of PI3K/AKT signaling pathway components
04

Disease associations

Cancer (notably endometrial carcinoma)Likely roles in other oncogenic settings (lncRNA family function)
05

Safety considerations

Therapeutic targeting of lncRNAs presents general challenges: specificity, delivery, unknown off-target effects, potential impact on physiological regulatory networksNo safety data are yet available for drugs targeting LINC01170 specifically (no clinical candidate exists as of latest literature)
06

Biomarkers

Overexpression of LINC01170 in tumor tissue is a biomarker for poor prognosis in endometrial carcinomaAssociated with advanced stage and metastatic progression

Beyond the preview

Go deeper on Long intergenic non-protein coding RNA 1170 (LINC01170).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Long intergenic non-protein coding RNA 1170 (LINC01170).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call